Orion Porfolio Solutions LLC Grows Position in Medtronic PLC $MDT

Orion Porfolio Solutions LLC boosted its position in shares of Medtronic PLC (NYSE:MDT) by 28.0% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 121,441 shares of the medical technology company’s stock after acquiring an additional 26,565 shares during the quarter. Orion Porfolio Solutions LLC’s holdings in Medtronic were worth $11,566,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in MDT. Vanguard Group Inc. grew its position in shares of Medtronic by 1.5% during the second quarter. Vanguard Group Inc. now owns 126,909,406 shares of the medical technology company’s stock worth $11,062,693,000 after acquiring an additional 1,895,165 shares during the last quarter. Geode Capital Management LLC boosted its stake in Medtronic by 1.1% during the 2nd quarter. Geode Capital Management LLC now owns 28,227,006 shares of the medical technology company’s stock worth $2,448,699,000 after purchasing an additional 310,684 shares during the period. Bank of New York Mellon Corp boosted its stake in Medtronic by 0.9% during the 3rd quarter. Bank of New York Mellon Corp now owns 21,468,260 shares of the medical technology company’s stock worth $2,044,637,000 after purchasing an additional 192,410 shares during the period. Massachusetts Financial Services Co. MA grew its position in Medtronic by 0.5% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 21,086,499 shares of the medical technology company’s stock worth $2,008,278,000 after purchasing an additional 98,220 shares during the last quarter. Finally, Invesco Ltd. increased its stake in Medtronic by 3.9% in the second quarter. Invesco Ltd. now owns 17,647,149 shares of the medical technology company’s stock valued at $1,538,302,000 after purchasing an additional 666,557 shares during the period. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on MDT. Daiwa Securities Group reduced their target price on shares of Medtronic from $117.00 to $115.00 and set a “buy” rating for the company in a report on Friday, February 27th. Royal Bank Of Canada boosted their price target on Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a research report on Wednesday, November 19th. Mizuho raised Medtronic to a “strong-buy” rating in a research report on Wednesday, February 18th. The Goldman Sachs Group set a $111.00 target price on Medtronic and gave the company a “neutral” rating in a report on Wednesday, November 19th. Finally, TD Cowen restated a “buy” rating on shares of Medtronic in a research note on Friday, November 14th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $110.74.

Insider Activity at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of the company’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the transaction, the executive vice president directly owned 32,768 shares of the company’s stock, valued at $3,201,761.28. This represents a 61.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.26% of the company’s stock.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Board approved a cash dividend of $0.71 for Q4 FY2026, reinforcing Medtronic’s long track record as a dividend grower and supporting income‑focused investor demand. Medtronic announces cash dividend for fourth quarter of fiscal year 2026
• Positive Sentiment: Medtronic launched the MiniMed Go Smart MDI system with the Simplera sensor in Europe, expanding its connected diabetes portfolio and addressing long‑term growth in continuous glucose monitoring and smart‑pen integration. Medtronic’s New MiniMed Go Highlights Digital Diabetes Push And Valuation Gap
• Positive Sentiment: Medtronic and GE HealthCare expanded their patient‑monitoring alliance, which could broaden distribution for products like Nellcor pulse oximetry and support recurring revenue streams. Medtronic, GE HealthCare expand patient monitoring alliance
• Positive Sentiment: Industry reports continue to rank Medtronic among leaders in biosensors and continuous glucose monitoring, supporting the company’s strategic position in a fast‑growing addressable market. Biosensors Company Evaluation Report 2025
• Neutral Sentiment: MiniMed priced its IPO at $20.00 per share for 28,000,000 shares — a procedural step that establishes a public valuation for the diabetes unit but doesn’t by itself show how Medtronic will deploy proceeds or adjust ownership. MiniMed announces pricing of initial public offering
• Negative Sentiment: MiniMed’s US IPO raised roughly $560 million — the market is interpreting the spin‑out as a catalyst for MDT selling pressure because it shifts future diabetes growth and cash flows away from the parent and may prompt portfolio rebalancing by investors. Medtronic’s diabetes unit MiniMed raises $560 million in US IPO

Medtronic Stock Performance

NYSE MDT opened at $92.96 on Friday. The stock has a market capitalization of $119.35 billion, a price-to-earnings ratio of 25.89, a PEG ratio of 2.40 and a beta of 0.71. The business’s 50 day moving average is $98.80 and its two-hundred day moving average is $96.95. Medtronic PLC has a 12-month low of $79.55 and a 12-month high of $106.33. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The business had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. During the same period last year, the firm earned $1.38 EPS. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Research analysts expect that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be given a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 3.1%. The ex-dividend date is Friday, March 27th. Medtronic’s payout ratio is presently 79.11%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).